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Oncogenic mutations of FLT3 and KIT receptors are associated with poor survival in patients with 
acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN) and currently available 
drugs are largely ineffective. Although Stat5 has been implicated in regulating several myeloid 
and lymphoid malignancies, how precisely Stat5 regulates leukemogenesis, including its nuclear 
translocation to induce gene transcription is poorly understood. In leukemic cells, we show 
constitutive activation of focal adhesion kinase (FAK), whose inhibition represses 
leukemogenesis. Downstream of FAK, activation of Rac1 is regulated by RacGEF Tiam1, whose 
inhibition prolongs the survival of leukemic mice. Inhibition of the Rac1 effector PAK1 prolongs 
the survival of leukemic mice in part by inhibiting the nuclear translocation of Stat5. These results 
reveal a leukemic pathway involving FAK/Tiam1/Rac1/PAK1 and demonstrate an essential role 
for these signaling molecules in regulating the nuclear translocation of Stat5 in leukemogenesis.
INTRODUCTION
Acute myeloid leukemia (AML) is a lethal disease characterized by uncontrolled growth of 
myeloid cells and is predominantly a disease of the elderly. Little progress has been made in 
terms of standard of care treatment for AML, which has essentially remained the same over 
decades. Long-term survival is observed in ~ 30% of younger patients and ~5% of older 
patients greater than 60 years of age. Internal tandem duplications (ITD), in-frame insertions 
or duplication of amino acids near the juxtamembrane domain of FLT3, have been observed 
in ~25 to 30% of all AML patients and confer a poor prognosis (Kottaridis et al., 2001). 
Likewise, gleevec resistant activation loop mutations of KIT (KITD816V) are found in a 
number of patients with core binding factor (CBF)-AML and ~95% patients with systemic 
mastocytosis (SM) and confer poor overall survival (Beghini et al., 2004). Both FLT3ITD 
and KITD816V receptors are constitutively phosphorylated (Kiyoi et al., 2002; Spiekermann 
et al., 2003) and induce growth in a ligand-independent manner. While effort has been 
devoted to the development of FLT3 and KIT inhibitors; as single agents, the efficacy of 
these inhibitors is limited and in some cases results in drug resistance (Smith et al., 2012). 
Given that direct targeting of FLT3ITD or KITD816V has met with little success, signaling 
pathways downstream from FLT3ITD/KITD816V provide attractive alternate targets for 
treating hematologic malignancies involving these receptors.
Overexpression of focal adhesion kinase (FAK) in up to 50% of AML patient derived cells 
but not in normal cells has been observed, and FAK is hyper-phosphorylated on Y397 in a 
number of patients. FAK+ AML cells show greater migration and resistance to daunorubicin 
compared to FAK- cells and FAK expression correlates with high blast cell counts, early 
death and shorter survival rate (Despeaux et al., 2011; Recher et al., 2004) (Li and Hua, 
2008). Presence of phosphorylated (p) pStat5 in newly diagnosed AML patients is also 
associated with poor overall survival (Brady et al., 2012). Constitutive activation of pStat5 is 
observed in 100% of systemic mastocytosis (SM) patients bearing the KITD816V mutation 
(Baumgartner et al., 2009). A strong correlation between the presence of pStat5 and 
FLT3ITD mutations is seen in AML patients and FLT3ITD expression results in constitutive 
Stat5 phosphorylation (Obermann et al., 2010) (Spiekermann et al., 2003), (Choudhary et 
al., 2007; Choudhary et al., 2005). Mutating the binding sites for Stat5 in the FLT3ITD 
abrogates the development of MPN (Rocnik et al., 2006). Taken together, studies suggest 
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that FLT3ITD/KITD814V, FAK and Stat5 may be involved in regulating a critical pathway 
in AML and MPNs; however, the relationship between these signaling molecules in the 
context of leukemogenesis is not fully understood. Importantly, although Stat5 has been 
implicated in regulating several hematologic malignancies; how precisely activation of Stat5 
is regulated in the cytosol or in the nucleus of leukemic cells and what are the signaling 
molecules involved in its nuclear import in the context of AML or MPN remains unclear. 
Here we reveal a leukemic pathway involving FAK/Tiam1/Rac1/PAK1 and demonstrate an 
essential role for these signaling molecules in regulating the nuclear translocation of Stat5 in 
leukemogenesis.
RESULTS
FAK is constitutively phosphorylated in FLT3ITD and KITD814V expressing cells
32D cells expressing the WT FLT3 or KIT receptor (FLT3WT or KITWT) or its oncogenic 
version (FLT3ITD or KITD814V) were starved and treated with a FAK specific inhibitor 
F-14 (Golubovskaya et al., 2008). Enhanced activation of FAK was observed in FLT3ITD 
bearing cells compared to controls (Fig.1A, lane1 vs 5), which was inhibited in the presence 
of F-14 (Fig.1A, lane 6 vs 5). Similar results were observed in cells expressing KITWT and 
KITD814V receptors (Fig.1B). To assess if activation of FAK was restricted to oncogenic 
FLT3 and KIT receptor expressing cells, same cells were stimulated with IL-3 to activate the 
IL-3 receptor, and analyzed for FAK activation. As seen in Figure 1A (lane 3), IL-3 
stimulation also resulted in activation of FAK, which was inhibited in the presence of F-14 
(Fig.1A, lane 4). Similar results were observed upon treatment of cells with FLT3 ligand 
(FL) (Fig.1C, lane 1 vs 3). To assess the direct involvement of FLT3ITD in FAK activation, 
cells were treated with AC220, a potent FLT3ITD inhibitor (Smith et al., 2012). Treatment 
of FLT3ITD cells with AC220 inhibited the activation of FLT3ITD (Fig.1D, lane 3 vs 4) 
and also resulted in reduced FAK activation (Fig.1E, lane 1 vs 3). To rule out the non-
specific effects of F-14 on FAK inhibition, we utilized a genetic approach. WT BM cells 
expressing KITD814V demonstrated increased levels of active FAK compared to controls, 
while FAK−/− BM cells showed absence of FAK expression (Fig.1F). FLT3ITD+ve AML 
patient derived cells also demonstrated constitutive FAK activation, which was inhibited in 
the presence of F-14 (Fig.1G). Figures 1D and S8D show the expression of total FLT3 and 
KIT receptors. We also performed intracellular staining to determine the effect of Y-11; 
another FAK specific inhibitor (Golubovskaya et al., 2012) on FLT3ITD mediated 
repression of FAK. As seen in Figure 1H, the percentage of cells showing activated FAK 
was significantly higher in FLT3ITD expressing cells (83.1%, middle panel) as compared to 
WT (19.2%) (left vs middle panel). Treatment of FLT3ITD cells with Y-11 inhibited the 
activation of FAK (69.7%, right panel), and correspondingly increased the levels of un-
phosphorylated FAK (30.3%) compared to vehicle treated (16.9%) (right panel vs middle 
panel). These results suggest that FAK is hyperactive in FLT3 and KIT oncogene bearing 
cells and pharmacologic inhibition or genetic loss of FAK can repress the activation of FAK 
in these cells.
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Inhibition of FAK suppresses the constitutive growth of oncogenic FLT3 and KIT 
expressing cells
We assessed the functional significance of constitutive activation of FAK in FLT3ITD 
expressing cells. As seen in Fig.2A, treatment of BaF3 cells with F-14 significantly 
repressed the ligand independent growth of FLT3ITD bearing cells in a dose dependent 
manner, with minimal effect on FLT3WT expressing cells. Similar growth repression was 
seen in 32D cells treated with Y-11 (Fig.2B). Expression of FRNK, a dominant negative 
version of FAK (Zhao and Guan, 2009), also repressed the ligand independent growth of 
FLT3ITD expressing cells (Fig.2C), which was partly a result of reduced survival 
(Fig.S1A,B). Expression of FRNK in FLT3 cells is shown in Fig.S8D. Although these 
results suggest an essential role for FAK in ligand independent growth of FLT3ITD 
expressing cells, a direct role of FAK was ascertained by complete ablation of FAK. As seen 
in Fig.2D, expression of FLT3ITD in WT BM cells (FAK+/+) demonstrated ligand 
independent growth, which was significantly repressed in FAK−/− cells. We also assessed 
whether targeting hyperactive FAK in cell lines derived from human leukemic patients, 
shows similar effects. We used MV4-11 and HL60 cells that express the FLT3ITD and WT 
receptors, respectively. Treatment of MV4-11 cells with Y-11 showed a dose dependent 
repression of constitutive growth (Fig.2E), while no such effect was observed in HL60 cells 
(Fig.2F).
To assess whether FAK plays a similar role in cells bearing an oncogenic form of KIT 
(KITD816V in humans and KITD814V in mouse); we used 32D cells expressing WTKIT or 
KITD814V. As seen in Fig.2G, treatment of these cells with Y-11 resulted in growth 
repression of KITD814V expressing cells. Similar results were observed upon Y-11 
treatment of HMC1.2 cells derived from a human mastocytosis patient bearing the activating 
KIT mutation (Fig.2H). These results show that FAK plays an essential role in supporting 
the constitutive growth of FLT3 and KIT oncogene bearing hematopoietic cells which is 
modulated by pharmacologic or genetic inhibition of FAK.
AC220 resistant “driver” mutations of FLT3 are sensitive to FAK inhibition
Recent translational studies validated FLT3ITD mutations in AML to function as “driver” 
but not “passenger” mutations (Smith et al., 2012). Smith et al. demonstrated the presence of 
point mutations at three residues within the kinase domain of FLT3ITD that conferred 
resistance to AC220, an inhibitor of FLT3 and KIT. Acquisition of AC220 resistant 
substitutions at two of these residues was observed in all FLT3ITD+ AML patients with 
acquired resistance to AC220, thus validating FLT3ITD to function as a driver mutation and 
a critical therapeutic target in AML. We assessed whether these mutants were sensitive to 
FAK inhibition. As seen in Fig. 3A, AC220 resistant FLT3 kinase domain mutant (D835Y, 
F691L and D835V) induced growth is inhibited by F-14.
AML FLT3ITD+ and KITD816V+ SM patient derived cells are sensitive to FAK inhibition
We next assessed whether inhibition of FAK in primary FLT3ITD+ AML cells inhibits their 
growth. We examined cells derived from 16 independent patients. Data from four 
representative patients is shown. In Figure 3B, a dose dependent reduction in the growth of 
all FLT3ITD+ AML cells was observed in the presence of F-14 and Y-11. Likewise, SM 
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patient derived cells positive for KITD816V mutation also demonstrated significantly 
greater growth reduction relative to patients lacking the expression of KITD816V (Fig. 3C). 
These results demonstrate that FAK is indeed hyperactive in FLT3ITD and KITD816V 
expressing cells and its inhibition is associated with enhanced apoptosis and growth 
repression.
FAK and Rac1 modulate the nuclear translocation of active Stat5 in FLT3 and KIT 
oncogene expressing cells
In an effort to identify downstream targets of FAK that might contribute to FLT3ITD 
induced growth and enhanced survival, we examined the activation of PI3Kinase, ERK 
MAP Kinase as well as RacGTPases. In non-hematopoietic cell types, all three pathways 
have been shown to be regulated by FAK (Gabarra-Niecko et al., 2003; Yin, 2011). We 
found constitutive and enhanced activation of Rac1 in FLT3ITD bearing cells relative to 
FLT3WT bearing cells (Fig.4A; lanes 1 & 2 vs 4 in control [CT] panel). Expression of 
FRNK in FLT3ITD expressing cells significantly inhibited the constitutive activation of Rac 
(Fig.4A; lane 3, control [CT] panel). Furthermore, treatment of these cells with F-14 
abolished Rac activation (lanes 1-4 upper control [CT] panel vs. lanes 1-4 lower [F-14] 
panel) (Fig.4A). A similar reduction in Rac activation was also observed in FLT3ITD+ve 
human leukemic MV4-11 cells and FLT3ITD+ AML patient derived cells, respectively 
(Figs. 4B, 4C); as well as in FAK−/−deficient cells expressing FLT3ITD (Fig.4D). shRNA 
mediated down-regulation of FAK in FLT3ITD bearing cells also showed similar results 
(Fig.4E). These results suggest that FAK plays a role in the activation of Rac1 in FLT3ITD 
bearing cells. Consistent with these observations, treatment of cells with a Rac1 inhibitor 
NSC23766 repressed the constitutive growth of FLT3ITD+ AML patient derived cells and 
of MV4-11 leukemic cells expressing the FLT3ITD receptor (Fig.S1C,D). HL60 cells that 
express the FLT3WT receptor were used as a negative control (Fig.S1E). Similar findings 
were observed in FLT3ITD bearing cells expressing a dominant negative version of Rac 
(RacN17) (Fig.S1F).
Active Stat5 is thought to play an essential role in regulating the transformation of FLT3 and 
KIT oncogene bearing cells (Baumgartner et al., 2009; Brady et al., 2012). Although Stat5 is 
a transcription factor, mechanism(s) involved in the transport of this molecule in and out of 
the nucleus in oncogene bearing cells remains poorly understood. We therefore performed 
cellular fractionation assays to determine the mechanism(s) behind active Stat5 translocation 
into the nucleus mediated by Rac1 and its upstream activator FAK in oncogene bearing 
cells. We found active Stat5 in the nuclear fractions of FLT3ITD bearing cells, which was 
associated with enhanced presence of Rac1, as compared with cells expressing FLT3WT 
(Fig.5A, lanes 1 vs 3). To determine whether nuclear translocation of Stat5 could be 
mimicked in FLT3WT expressing cells upon cytokine stimulation, cells were treated with 
IL-3 and analyzed for Stat5 and Rac1 localization. As seen in Figure 5A (lane 2), addition of 
IL-3 resulted in activation of FLT3WT mediated Stat5-Rac1 nuclear localization, which was 
inhibited in the presence of F-14 (Fig.5B, lane 1 vs 2). Next, we assessed if the effect of 
FAK inhibition could be overcome after ligand stimulation. FLT3ITD expressing cells were 
treated with FLT3 ligand, followed by treatment with F-14. As seen in Figure 5B, 
stimulation of FLT3ITD with its ligand FL resulted in a modest increase in nuclear localized 
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active Stat5 and Rac1 (Fig.5B, lane 1 vs 3) (Zheng et al., 2011), which was repressed in the 
presence of F-14 (Fig.5B, lane 4). A similar reduction in the activation of Stat5, and 
accumulation of Rac1, respectively was noted in the nuclear fractions of primary FLT3ITD+ 
AML (Fig.S2A), KITD816V+ mastocytosis (HMC1.2) (Fig.5C), and AML patient derived 
cells (MV4-11) treated with F-14 (Fig.5D). HL60 cells that express the FLT3WT receptor 
served as a negative control (Fig.5D, right panels). AC220 resistant “driver” mutations of 
FLT3 also demonstrated reduced nuclear accumulation of active Stat5 and total Rac1, 
respectively when treated with F-14 (Fig. S2B). Although we did not observe inhibition in 
the activation of MAPKinase or PI3Kinase/Akt pathway in FLT3ITD bearing cells lacking 
FAK or in which FAK was inhibited, we nonetheless directly examined the contribution of 
these pathways in the nuclear translocation of Stat5 and total Rac1. We performed a 
fractionation assay in the presence of MEK (PD98059) or Raf (PLX4720) or Akt (124005) 
inhibitor and observed no significant inhibition of Rac1 or active Stat5 nuclear translocation 
(Fig.S2C). Raf and MEK inhibitors also failed to repress the constitutive growth of 
FLT3ITD bearing cells (Figs.S2D, E).
A direct role for FAK in regulating the translocation of active Stat5 can be seen in Fig.S2F. 
Expression of FLT3ITD failed to translocate active Stat5 and total Rac1 to the nucleus in 
FAK−/− deficient BM cells (Fig.S2F, lane 1 vs 2). The expression of FLT3 receptor in WT 
(FAK+/+) and FAK−/− BM cells is shown in Fig.S8E. To further understand the 
mechanism behind FAK regulated Stat5 translocation in FLT3 and KIT oncogene bearing 
cells in an in vivo setting, we used cells derived directly from mice that were transplanted 
with BM from WT (FAK+/+) and FAK deficient (FAK−/−) mice expressing KITD814V. 
Mice transplanted with WTFAK BM cells expressing KITD814V came down with disease 
significantly earlier than FAK−/− KITD814V mice (Fig.7G), at which point time-point 
matched control mice (FAK−/− KITD814V) were euthanized and BM cells harvested from 
both groups of mice and subjected to cellular fractionation analysis. As seen in Fig.5E (lane 
1 vs 2), and consistent with our in vitro findings (Fig.S2F), genetic ablation of FAK in vivo 
inhibited the nuclear translocation of active Stat5 and Rac1 in KITD814V bearing BM 
derived leukemic cells. Furthermore, similar results were also observed after F-14 treatment 
of leukemic mice transplanted with BM cells expressing KITD814V. As seen in Figure 5F, 
BM cells derived from leukemic mice bearing the KITD814V mutation that were treated 
with F-14 also showed a reduction in Stat5 activation and nuclear accumulation of Rac1, as 
compared to cells derived from vehicle (DMSO) treated mice (Fig.5F, lane 1 vs 2).
Active Stat5 downstream of FLT3ITD translocates to the nucleus to bind DNA and express 
Stat5 responsive genes like c-Myc and BclXL that play a crucial role in leukemogenesis (Li 
et al., 2007; Zhang et al., 2000). We next performed qRT-PCR analysis to determine the 
relative expression of c-Myc and BclXL genes in FLT3ITD cells treated with F-14. As seen 
in Figures 5G and 5H, a significant reduction in the expression of Stat5 responsive genes c-
Myc and BclXL was observed upon FAK inhibition. Similar results were observed in FAK
−/− FLT3ITD cells (Fig.S3A, B). To ascertain whether FAK also regulates the nuclear 
association between Rac1 and Stat5, besides directly activating Rac1, F-14 treated nuclear 
fractions were subjected to Rac1 immunoprecipitation assay. As seen in Fig.6A, the amount 
of active Stat5 that interacts with Rac1 was significantly reduced upon treatment of 
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FLT3ITD cells with F-14 (Fig.6A, lane 1 vs 2). These results explain our initial observation 
demonstrating that reduced levels of total Rac1 and active Stat5 in nuclear fractions of 
FLT3ITD bearing cells in which FAK activation was repressed, and is directly a 
consequence of FAK's role in the activation of Rac1, and more importantly its association 
and subsequent translocation with active Stat5 into the nucleus. To further assess whether 
FAK regulates the association between active Rac1 and active Stat5, we performed active 
Rac1 pull down assay from WT and FAK−/− BM cells expressing FLT3ITD and analyzed 
for active Stat5 binding. As seen in Fig.6B, increased levels of active and total Stat5 protein 
was bound to activated Rac1 in WT (FAK+/+) BM cells (lane 1), which was reduced in 
FAK deficient (FAK−/−) FLT3ITD bearing cells (lane 2). Taken together, these findings 
suggest that first, FAK regulates the formation of an active Rac1-active Stat5 complex and 
second, it modulates the translocation of Rac1-Stat5 complex into the nuclear compartment.
Since Rac1 contains a functional nuclear localization signal (NLS), and also forms a 
complex with active Stat5 in the nucleus, we next investigated the role of Rac1 in nuclear 
translocation of active Stat5 in FLT3ITD-bearing cells. Cells were treated with or without 
Rac inhibitor NSC23766, and subjected to a fractionation assay. Levels of active Stat5, 
along with total Rac1, were reduced in FLT3ITD cells treated with NSC23766 (Fig.S3C). 
Likewise, cells co-expressing FLT3ITD along with a dominant negative form of Rac1 
(Rac1N17) showed reduced levels of active Stat5 in the nuclear fractions (Fig.S3D). Equal 
expression levels of GFP-Rac1N17 in FLT3ITD and WT cells can be seen in Fig.S3E,F. As 
seen in Fig.6C (lane 1 vs 2), robust levels of active Stat5 were present in nuclear fractions of 
FLT3ITD expressing Rac1+/+ BM cells, while a significant reduction in the levels of 
nuclear localized active Stat5 was observed in Rac1−/− BM cells, with no detectable levels 
of Stat5 activation in FLT3WT bearing cells. These results demonstrate an essential role for 
Rac1 in the translocation of active Stat5 into the nucleus.
RacGEF Tiam1 is essential for FLT3ITD induced leukemic development in mice
To identify RacGEFs involved downstream of FAK in activating Rac1 in FLT3ITD bearing 
cells, we analyzed the role of Tiam1. We ascertained whether Tiam1 is active in cells 
bearing FLT3ITD. As seen in Figure 6D, increased levels of active Tiam1 were observed in 
FLT3ITD bearing cells compared to FLT3WT expressing cells (lane 1 vs 3), which was 
attenuated upon treating these cells with F-14 (lane 1 vs 2). Further, F-14 treatment 
perturbed the interaction between Rac1 and Tiam1 (Fig.6E). Having observed the presence 
of Tiam1 in active Rac1 complex in FLT3ITD bearing cells, and the perturbation of this 
association upon FAK inhibition, we next examined the functional significance of Tiam1 in 
FLT3ITD induced transformation. We knocked down Tiam1 using shRNA in cells bearing 
FLT3ITD (Fig. S3G). Cells bearing FLT3ITD and Tiam1 shRNA showed significant 
reduction in constitutive growth in comparison to cells bearing scrambled shRNA 
(Fig.S3H). Moreover, when FLT3ITD and Tiam1shRNA co-expressing cells were subjected 
to a fractionation assay, the levels of active Stat5 and total Rac1 in nuclear fractions were 
significantly reduced compared to scrambled shRNA expressing cells (Fig.6F, lane 1 vs 
2-5). As shown in Fig.6G (lane 1 vs 2-4), knockdown of Tiam1 significantly inhibited the 
activation of Rac1 compared to cells co-expressing FLT3ITD and scrambled shRNA. These 
results indicate that Tiam1 plays an important role in the activation of Rac1 in FLT3ITD 
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expressing cells, which in-turn regulates the nuclear translocation of the Rac1/Stat5 
complex. To further investigate the role of Tiam1 in FLT3ITD induced leukemogenesis, we 
performed transplantation experiments. Fig.6H shows that mice transplanted with FLT3ITD 
and Tiam1 shRNA survived significantly longer compared to mice transplanted with 
FLT3ITD and scrambled vector (*p<0.01).
Inhibition of FAK delays the onset of FLT3ITD and KITD814V induced MPN development 
and prolongs the survival of mice
We next examined the in vivo impact of FAK inhibition on FLT3ITD and KITD814V 
induced leukemogenesis. Although mice bearing FLT3ITD cells treated with DMSO died 
within 30 days post-transplant, mice treated with F-14 showed significantly prolonged 
survival (Fig.7A). F-14 treated mice showed significantly reduced spleen weight (Fig.7B,C), 
and demonstrated absence of lesions in lungs compared to DMSO treated mice (Fig.S4A,B). 
Histopathologic analysis showed leukemic infiltration of myeloid cells and destruction of 
alveolar architecture in lungs and of normal architecture in spleens of DMSO treated mice 
but significant improvement in the F-14 treated mice (Fig.S4C,D). Moreover, F-14 treated 
mice also showed reduced percentage of leukemic cells in tissues (peripheral blood and 
spleen) as determined by the presence of GFP positive cells (Fig.S4E,F), relative to vehicle 
treated mice. Likewise, F-14 treatment of mice transplanted with cells expressing 
KITD814V survived significantly longer than vehicle treated mice (Fig.S5A, *p<0.01). We 
next assessed these findings in mice transplanted with primary BM cells expressing 
KITD814V. One cohort of mice was treated with F-14 and the other with vehicle (DMSO). 
As seen in Figure 7D, WBC counts remained constant over the entire duration of F-14 
treatment in KITD814V bearing mice (6 weeks), while KITD814V bearing mice treated 
with vehicle demonstrated a steady rise in WBC counts over time, a hallmark of MPN 
development and progression. At the end of 6 weeks, all mice were euthanized and 
analyzed. As seen in Fig. 7E, F, vehicle treated mice demonstrated significant enlargement 
of spleen compared to F-14 treated mice. Collectively, these data supports the observation 
that targeting FAK rescues the development of FLT3ITD and KITD814V induced MPN in 
vivo. To further investigate the role of FAK in FLT3ITD induced MPN, we knocked down 
FAK expression using shRNA in cells bearing FLT3ITD and transplanted into mice as 
described in Fig.7A. Knockdown of FAK not only repressed the constitutive growth of 
FLT3ITD bearing cells (Fig.S5B), but more importantly mice transplanted with cells co-
infected with FLT3ITD and FAK shRNA survived significantly longer compared to mice 
transplanted with FLT3ITD and scrambled vector (Fig.S5C, *p<0.025). To rule out non-
specific effects of F-14, and diminished but not absolute effects of shRNA mediated 
knockdown of FAK, we performed transplantation studies using primary BM cells from WT 
(FAK+/+) and FAK−/− deficient mice expressing the oncogenic KITD814V receptor. As 
seen in Figure 7G, genetic ablation of FAK significantly prolonged the survival of leukemic 
mice (FAK−/− KITD814V) compared to controls (FAK+/+ KITD814V). Leukemic mice 
harboring the KITD814V oncogene in the FAK−/− background demonstrated reduced 
spleen size (Fig.7H, I) and WBC counts relative to controls (Fig.S5D). To further ascertain 
whether targeting FAK in the context of KITD814V induced MPN inhibits the growth of 
cells that give rise to leukemia; we performed secondary transplants using BM cells derived 
from the primary cohorts. As seen in Figure 7J, mice transplanted with BM cells from 
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primary donor harboring KITD814V in a FAK deficient background (FAK−/− KITD814V) 
survived significantly longer than mice transplanted with BM from WT background (FAK
+/+ KITD814V). The prolonged survival of these mice correlated with reduced 
splenomegaly (Figs. 7K, L). Importantly, loss of FAK in HSCs did not impair the 
engraftment or the self-renewal of these cells (Lu et al., 2012).
Targeting PAK1 inhibits the nuclear translocation of active Stat5
To determine the functional role of p21-activated kinase (PAK), a downstream effector of 
Rac1, in Stat5 regulation and leukemogenesis, we utilized a recently described allosteric 
PAK inhibitor, IPA-3 (Deacon et al., 2008). As seen in Fig.8A (lane 5 vs 7), IPA-3 
treatment significantly inhibited the presence of activated nuclear Stat5 in FLT3ITD 
expressing cells. As seen in Fig.8A (lane 1 vs 2), addition of ligand also resulted in 
activation of the Stat5 oncogenic pathway in FLT3WT cells, which was also inhibited by 
IPA-3 (Fig.8A, lane 4). Next, we used another PAK inhibitor PF-3758309 (PF) (Murray et 
al., 2010). As seen in Figure 8B (lane 1 vs 2), similar results were observed upon treating 
FLT3ITD cells with PF-3758309 resulting in repression of nuclear translocation of active 
Stat5. Consistent with these results, expression of a dominant negative form of PAK1 
(K299R), in FLT3ITD expressing cells (Fig.S5F) demonstrated reduced tyrosine 
phosphorylated Stat5 (Fig.S5E). These results suggest that downstream from Rac1, PAK 
contributes to the translocation of active Stat5 in the nucleus in FLT3ITD bearing cells. To 
determine whether PAK is active in FLT3ITD and KITD814V oncogene bearing cells, 
whole cell lysates were analyzed for PAK1 activity. As seen in Figure S6A, cells expressing 
KITD814V showed increased levels of constitutive PAK1 activation (pPAK1) compared to 
KITWT cells (lane 1 vs 5), which was readily inhibited upon treatment with F-14 (lane 2, 6). 
Similar results were seen in FLT3ITD expressing cells treated with F-14 (Fig.S6B, lane 1 vs 
2). Inhibition of active PAK1 levels were also observed in FLT3ITD expressing cells treated 
with PAK inhibitors IPA-3 and PF-3758309 (Fig.S6C, lane 1 vs 2-3). These results suggest 
that PAK1 is hyperactive downstream of a FAK/Rac1 signaling pathway in FLT3ITD and 
KITD814V oncogene bearing cells.
Group I family of PAKs consist of three members including PAK1, PAK2 and PAK3. While 
PAK1 and PAK2 are ubiquitously expressed, PAK3's expression is predominantly restricted 
to the brain (Ye and Field, 2012). We assessed the role of PAK1 and PAK2 in oncogene 
induced transformation by examining Stat5 activation in FLT3ITD cells in which the 
expression of these two isoforms was knocked down (Fig.S6E). As seen in Fig.S6D, 
knockdown of PAK1 (lane 1 vs 2-3) but not PAK2 (lane 1 vs 4-6) significantly reduced the 
nuclear accumulation of active Stat5 in FLT3ITD expressing cells. Consistent with these 
findings, expression of FLT3ITD in PAK1 deficient BM (PAK1−/−) cells also impaired the 
nuclear translocation of active Stat5 (Fig.S6I, lane 1 vs 2). Furthermore, loss of active Stat5 
nuclear import in PAK1−/− FLT3ITD cells resulted in reduced expression of Stat5 target 
genes including Bcl-xL and c-Myc compared to controls (Fig.S6F), and also reduced 
relative mRNA levels of c-Myc and BclXL in FLT3ITD cells treated with PAK inhibitor 
PF-3758309 (Fig. 8C,D).
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Inhibition of PAK1 delays the onset of FLT3ITD and KITD814V induced MPN and prolongs 
the survival of mice
To determine the role of PAK isoforms in FLT3ITD and KITD814V mediated MPN 
development, BM transplant studies were performed. Transplantation studies utilizing 
myeloid cells bearing FLT3ITD in the context of PAK2 knockdown did not prolong the 
survival of leukemic mice compared to controls (Fig.S6G). In contrast, PAK1 knockdown in 
the context of FLT3ITD expression significantly enhanced the life span of leukemic mice 
(Fig.S6H). To further confirm PAK1's involvement in KITD814V mediated 
leukemogenesis, we transplanted mice with KITD814V bearing PAK1−/− BM cells or WT 
(PAK1+/+) controls. Mice transplanted with WTPAK1 BM cells expressing KITD814V 
came down with disease significantly earlier than PAK1−/− KITD814V mice (Fig.8G), at 
which juncture time-point matched control mice (PAK1−/− KITD814V, PAK1+/+ KITWT, 
PAK1−/− KITWT) were euthanized and BM (Fig.8E) and spleen (Fig.8F) cells harvested 
and subjected to cellular fractionation analysis. As seen in Figure 8E (lane 1 vs 2) and 8F 
(lane 1 vs 2), similar to our data using cell lines and PAK inhibitors, genetic ablation of 
PAK1 in vivo abrogated the nuclear translocation of active Stat5 in KITD814V bearing BM 
derived cells. As seen in Figure 8G, genetic ablation of PAK1 significantly prolonged the 
survival of leukemic mice (PAK1−/− KITD814V) compared to controls (PAK1+/+ 
KITD814V), and modulated the development of MPN in mice as shown by reduced 
splenomegaly and WBC counts (Figs.8H, S6J,K). Mice transplanted with WTKIT did not 
demonstrate any signs of MPN, and showed normal survival and spleen size (Figs.8H, S6J). 
To further ascertain whether targeting PAK1 in the context of KITD814V induced MPN, 
selectively impacts the leukemia initiating cell ‘LIC’ population; we performed secondary 
transplants using BM cells from primary recipients. As seen in Figure 8I, mice transplanted 
with BM cells from primary donor harboring KITD814V in a PAK1 deficient background 
(PAK1−/− KITD814V) survived significantly longer than mice transplanted with BM from 
WT background (PAK1+/+ KITD814V). The survival of mice correlated with correction in 
spleen size (Figs. 8I,J, S6L), similar to primary transplants described above.
Inhibition of PAK inhibits the constitutive growth of FLT3ITD+ AML cells and KITD816V (+) 
SM patient derived cells
To assess the functional consequence(s) of PAK1 repression on the growth and transforming 
ability of FLT3ITD and KITD814V bearing cells, we performed a proliferation assay using 
cells expressing FLT3 and KIT receptors treated with or without PF-3758309. A dose 
dependent reduction in the growth of FLT3ITD and KITD814V bearing cells was observed 
but not that of FLT3WT and KITWT bearing cells (Fig.S7A,B and S7C,D, respectively). 
Similar results were observed for FLT3ITD cells treated with the PAK inhibitor IPA-3 
(Fig.S7E). To further validate these observations, we performed similar studies in FLT3ITD 
bearing cells co-expressing a dominant negative version of PAK1 (K299R) (Fig.S7F) as 
well as in BM cells expressing FLT3ITD in the setting of PAK1 deficiency (Fig.S7G). A 
significant inhibition in the growth of FLT3ITD bearing cells was noted in the background 
of dominant negative or genetic ablation of PAK1. A similar inhibition in the growth of 
AML patient cells (Fig.S7I) and KITD816V (+) SM patient derived cells (Fig.S7K) was 
observed in the presence of IPA-3. Lastly, we assessed the role of PAK1 overexpression on 
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the rescue of ligand-independent growth of BM cells expressing KITD814V in PAK1 
deficient (PAK1−/−) background. An activated version of PAK1 (PAK1T423E) 
(Schurmann et al., 2000) was co-expressed with KITD814V in BM cells derived from 
PAK1−/− mice. As seen in Figure S7H we observed rescue of ligand-independent growth of 
cells over-expressing PAK1T423E, as compared to vector control.
DISCUSSION
Presence of active Stat5 in the nucleus, and the subsequent expression of Stat5 dependent 
pro-survival and anti-apoptotic genes, plays a key role in the transformation of cells bearing 
oncogenic forms of FLT3 and KIT (Benekli et al., 2003; Choudhary et al., 2007; Tse et al., 
2000). However, the mechanism(s) involved in regulating the active form of nuclear Stat5 
remain poorly understood. To this end, a role for Rac1GTPase/MgcRacGAP complex in the 
translocation of active Stat5 into the nucleus has been suggested; however the upstream and 
downstream signaling proteins from Rac1 involved in this process have not been identified 
and the extent to which these proteins contribute to leukemogenesis is unknown (Sallmyr et 
al., 2008). Using pharmacologic, biochemical and genetic approaches, we demonstrate that 
the FAK/Rac1-Tiam1/PAK1 axis plays a crucial role in the transformation induced by 
oncogenic forms of FLT3 (FLT3ITD) and KIT (KITD816V). Targeting FAK, Tiam1, and 
PAK1 in oncogene bearing cells in vitro or in vivo inhibits the presence of active Stat5 in 
the nuclear compartment, which profoundly delays the onset of leukemia by repressing the 
expression of Stat5 responsive genes. These findings were validated in both murine and 
human models of AML and MPN and suggest that the signaling axis we have identified is 
highly conserved across species. More importantly, we show that this axis is active in 
leukemia initiating cells as well as in leukemic cells that acquire AC220 resistant mutations 
of FLT3.
We and others have shown that FAK may contribute to Rac activation in hematopoietic cells 
as well as in other heterologous cell systems (Chang et al., 2006; Elias et al., 2010; Vemula 
et al., 2010) and that FLT3ITD can activate Rac1 and regulate the production of reactive 
oxygen species (ROS) via its association with Stat5 (Sallmyr et al., 2008). Furthermore, 
active Rac1 can also induce the activation and nuclear translocation of Stat3 (Simon et al., 
2000). FLT3ITD can phosphorylate Stat5, independent of Jak kinase family members 
(Choudhary et al., 2007), while Rac1 mediated ROS production can induce the activation of 
Jak kinases and Stats downstream of G-protein coupled receptors (Pelletier et al., 2003). 
Although significant work has been done in identifying the above described linkages; how 
these molecules connect and what is their relationship in regulating transformation via 
oncogenic forms of KIT and FLT3 has never been described. Our findings provide insight 
into how FAK-Rac1-Tiam1 and PAK1 axis contributes to leukemic transformation in part 
by regulating active nuclear Stat5.
The role of GEFs such as Vav1 and Vav2 is largely considered promiscuous, as they 
regulate the activity of all three members of the RhoGTPase family including Rac, Rho and 
Cdc42 (Schmidt, 2002). In contrast, GEF Tiam1 is highly specific for Rac1 in vivo, and has 
been implicated in activating Rac1 to mediate Stat3 activation and its subsequent nuclear 
localization in COS-1 cells (Simon et al., 2000). We demonstrate that FAK activates Rac1 
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via RacGEF Tiam1 in FLT3ITD bearing cells, and targeting FAK and Tiam1 results in 
inhibition of Rac1. We also show that shRNA mediated knockdown of Tiam1 prolongs the 
survival of FLT3ITD bearing leukemic mice and genetic and pharmacologic inhibition of 
FAK and Tiam1 results in failure of active Stat5 to be expressed in the nucleus, along with 
Rac1. While Tiam1 regulates epithelial cancers such as carcinomas of breast and colon 
(Bourguignon et al., 2000; Buongiorno et al., 2008); we show its role in regulating 
hematologic malignancies.
Although evidence in this study and reported earlier (Sallmyr et al., 2008) suggests a role of 
Rac1 in translocating Stat5 into the nucleus, the relationship between Stat5 and RacGTPases 
in the context of FLT3 and KIT oncogenic mutations is unclear. An indirect role of PAK1 in 
nuclear shuttling of Stat5 has been suggested, where PAK1 plays a role in ‘switching’ in 
occupancy of the same promoter region between BCL6 and Stat5. In colorectal cancer 
PAK1, activated via Rac1, translocates into the nucleus and phosphorylates chromatin-
bound BCL6, leading to its dissociation from the promoter, thereby allowing active Stat5 
that is already present in the nucleus via a Rac1/MgcRacGAP dependent mechanism, to bind 
to the same promoter regions (Barros et al., 2012). In line with reported findings by Barros 
et al., we have observed a reduction in BCL6 activation and its mRNA expression levels 
upon treatment of FLT3ITD cells with PAK1 inhibitor (Fig.S8A, B). This data demonstrates 
that in the FLT3 and KIT oncogenic pathway the FAK/Tiam1/Rac1 signaling axis activates 
PAK1, which in-turn inhibits the transcriptional repressor BCL6, while correspondingly 
activating Stat5 to mediate leukemic transformation.
In BCR-ABL induced CML, majority of Stat5 is persistently active and retained in the 
cytoplasmic compartment, primarily via an association of active Stat5 with Gab2 and PI3k/
Akt, subsequently leading to leukemogenesis (Nyga et al., 2005). FLT3ITD also interacts 
with Gab2 and results in the activation of PI3K/Akt, Stat5 and Gab2 mediated recruitment of 
Src kinases can also result in the activation of Stat5. Thus, while FLT3ITD can directly 
activate Stat5 (Choudhary et al., 2007), other tyrosine kinases present in complexes with 
FLT3ITD may also be involved in regulating Stat5 activation including Src kinases, as 
mutating Src kinase binding sites Y589 and Y591 in FLT3 receptor inhibits Stat5 activation 
(Hayakawa et al., 2000; Rocnik, 2006). Our data using FLT3ITD specific inhibitor AC220 
not only shows inhibition in the phosphorylation of FLT3ITD on Y589/591, but also 
downstream inhibition of activating residue Y397 on FAK, indicating that oncogenic FLT3 
mediates direct activation of FAK. In breast cancer cells, Prolactin (PRL) induced activation 
of FAK and Stat5 is mediated via Src family kinases. Upon phosphorylation by Src, 
phosphorylated FAK recruits Grb2/Gab2 to mediate activation of Ras/MAPK signaling 
pathway. The involvement of the PI3K/Rac/Pak pathway in PRL-induced activation of Erk 
has also been suggested. These results demonstrate a complex cross-talk between various 
signaling pathways involved in breast cancer metastasis (Aksamitiene et al., 2011). Future 
studies will determine whether Gab2 or other Src kinases play a role in activating FAK 
downstream of FLT3ITD and KITD814V receptors, which results in oncogenic 
transformation mediated by the subsequent nuclear translocation of active Stat5.
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EXPERIMENTAL PROCEDURES
Antibodies and Reagents
Phycoerythrin (PE)-conjugated annexin V antibody and 7-amino actinomycin D (7-AAD) 
were purchased from BD Biosciences Pharmingen (San Jose, CA). Rabbit anti-phospho-
PAK1, anti-PAK1, anti-phospho-Stat5 (Y694), anti-Stat5 antibodies, rabbit anti-phospho-
FAK (Y397) and anti-FAK antibodies were purchased from Cell Signaling Technology 
(Beverly, MA). Anti-rabbit IgG DyLight 649 from Biolegend (San Deigo, CA), Anti-actin 
and GAPDH antibodies were purchased from Sigma (St. Louis, MO). Tiam1 activation kit 
was purchased from Cell BioLabs (San Diego, CA). Anti-mouse-HRP, anti-rabbit-HRP, 
anti-goat-HRP, anti-phospho-Stat5 (S780), anti-Tiam1, PARP-1, LaminB, BclXL and cMyc 
antibodies were purchased from Santa Cruz Biotechnology (Dallas,TX). FAK inhibitors 
F-14 and Y-11, PAK inhibitors IPA-3 and PF-3758309, and Rac inhibitor NSC23766 were 
purchased from R&D Systems Inc. (Minneapolis, MN). Lumina Forte Western HRP 
Substrate, Chemiluminescent Blocker (bløk-CH), anti-phospho-FAK (Y397) rabbit 
polyclonal, anti-Rac1 (23A8) and Rac1 activation kit were purchased from Millipore 
Corporation (Billerica, MA). Recombinant murine and human IL-3, Flt3, GM-CSF, SCF, 
IL-6, and Tpo were purchased from Peprotech (Rocky Hill, NJ). Retronectin was obtained 
from Takara (Madison, WI). Iscove's modified Dulbecco's medium (IMDM) was purchased 
from Invitrogen (Carlsbad, CA). Monothioglycerol was purchased from Sigma (St. Louis, 
MO). [3H] Thymidine was purchased from PerkinElmer (Boston, MA). Protein A– 
Sepharose beads were purchased from Amersham Biosciences (Piscataway, NJ). 
MKK/MEK inhibitor PD98059 was purchased from Cell Signaling Technology (Danvers, 
MA), Raf inhibitor PLX4720 from Selleckchem (Houston,TX) and Akt inhibitor 124005 
from Millipore corporation (Billerica, MA).
Mice
C57BL/6 and C3H/HeJ mice were purchased from Jackson Laboratory (Bar Harbor, ME). 
FAK, Rac1 and PAK1 deficient mice have been previously described (Martin et al., 2013; 
McDaniel et al., 2008; Vemula et al., 2010). All mice used in this study were between 6 to 
12 weeks of age and were maintained under specific pathogen-free conditions at the Indiana 
University Laboratory Animal Research Center (Indianapolis, IN). The studies were 
approved by the Institutional Animal Care and Use Committee (IACUC) of the Indiana 
University School of Medicine.
Patient Samples
Peripheral blood mononuclear cells from patients with AML were obtained at the time of 
diagnostic testing after informed consent. Approval was obtained from the institutional 
review boards of Indiana University School of Medicine. The buoyant fraction was isolated 
over Ficoll-Hypaque, and then washed with phosphate-buffered saline (PBS) before 
processing as described previously (Hartman et al., 2006). KITD816V positive or negative 
SM patient derived cells were obtained as described (Traina et al., 2012).
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Cells
Primary low density mononuclear cells (LDMNC) were harvested as described earlier and 
used in the study (Mali et al., 2011). The murine IL-3 dependent myeloid cell line 32D cells 
bearing FLT3, FLT3ITD (N51), MIEG3 vector, KIT, or KITD814V have been described 
(Mali et al., 2011). Puromycin resistant BaF3 cells bearing the AC220 resistant mutants 
(Flt3ITD+TKD_D835Y/F, F691L) have been described (Smith et al., 2012). The human 
mast cell leukemia line, bearing the KITV560G as well as KITD816V mutations, HMC1.2 
and acute myeloid leukemia (AML) cell line, bearing the FLT3ITD mutation, MV4-11 have 
been described (Butterfield et al., 1988; Lange et al., 1987).
Expression of WT and oncogenic receptors
Transduction of 32D and primary BM derived hematopoietic stem and progenitor cells was 
performed as described previously (Mali et al., 2011).
shRNA silencing of FAK, Tiam1 and PAK
FAK, Tiam1 or PAK-specific shRNA expression plasmids were purchased from OriGene 
Technologies (Rockville, MD). Purified and sequence verified plasmid containing a non-
effective 29-mer sh GFP cassette (Scrambled vector) was used as a negative control. Cells 
were transduced with scrambled vector or shRNA plasmid and grown in the presence of 
puromycin (10ng/mL) to select for the transduced cells.
Proliferation and Apoptosis assays
Proliferation assays were performed as previously described (Mali et al., 2011).
Cytoplasm and Nuclear extraction
To extract nuclear and cytosolic fractions, the NE-PER Nuclear and Cytoplasmic Extraction 
Kit (Thermo Scientific) was used as per the manufacturer's instructions.
Immunoprecipitation (IP) and Western blot analysis (WB)
Immunoprecipitation and western blot analysis was performed as described previously (Mali 
et al., 2011).
qRT-PCR
Total RNA was isolated from 5×106 cells using RNeasy Plus Mini Kit (Qiagen) according to 
the manufacturer's instructions. cDNA was generated using random hexamer primers and 
Superscript II reverse transcriptase (Invitrogen). qRT-PCR was performed using FastStart 
Universal SYBR Green master mix (Roche) and a Applied Biosystem 7500 Real Time PCR 
system. ß-actin amplification was used to normalize sample RNA content.
Mouse leukemia induction and in vivo drug treatment
Mouse leukemia induction and in vivo drug treatments were performed as described 
previously (Mali et al., 2011). 1×106 32D cells bearing FLT3ITD in 200 μL PBS was 
injected into C3H/HeJ mice intravenously. After 48 hours of transplantation, mice were 
treated with vehicle (PBS/DMSO) or FAK inhibitor F-14 (25 mg/kg body weight) by 
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intraperitoneal injection at 24 hour interval for 21 days. Mice were closely monitored for 
MPN development and harvested at moribund. For F-14 treatment in a primary transplant 
model, irradiated BoyJ mice were transplanted with 2.0 ×106 GFP-KITD814V cells and 0.1 
×106 supporting BM cells. Three weeks post-transplant mice were treated with 10 mg/kg 
body weight F-14 for 5 days a week, for 6 weeks. All mice were harvested and peripheral 
blood (PB) counts were monitored using a Hemavet 950 (Drew Scientific). PB, BM and 
spleens were analyzed for GFP expression. BM, spleen and lungs were also fixed in 10% 
buffered formalin to perform histopathologic analysis by hematoxylin and eosin (H&E) 
staining.
Statistics
All graphical data was evaluated by paired Student t- test (2-tailed) and results were 
considered significantly different with p-value <0.05. All data are represented as mean 
values ± standard deviations (SD). Survival probability of transplanted mice groups was 
compared using a Kaplan-Meier Survival Analysis in which statistical significance was 
determined as p-values <0.05 by log rank test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig.1. FAK is constitutively phosphorylated in FLT3 and activating KITD814V oncogene 
bearing cells
(A) Serum starved 32D cells expressing FLT3ITD and FLT3WT were treated with DMSO 
(lanes 1, 5); F-14 (lanes 2, 6); IL-3 (lanes 3, 7) or F-14 followed by IL-3 (lanes 4, 8). An 
equal amount of protein was subjected to western blot analysis and probed with phospho-
FAK (Y397) antibody (n=3). ‘MK’ denotes lane with protein ladder. (B) 32D cells 
expressing KITWT or KITD814V were treated with F-14 (n=2) and analyzed as described in 
(A). (C) 32D cells expressing FLT3WT were treated with F-14 (lane 2) or stimulated with 
FLT3 ligand (FL) (lane 3), and analyzed as described in (A). (D) 32D cells expressing 
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FLT3WT or FLT3ITD were treated with FLT3ITD inhibitor AC220 and analyzed for 
activated FLT3 (pY589/591). (E) 32D cells expressing FLT3ITD were treated with F-14 
(lane 2) or with AC220 (lane 3) (n=2) and analyzed as above. (F) Lysates from primary FAK
−/− deficient or WT BM cells expressing KITD814V or empty vector were analyzed for 
activated FAK. (G) FLT3ITD+ve AML patient sample was analyzed for activated FAK 
(n=2). (H) 32D cells expressing FLT3ITD were treated with Y-11 and subjected to flow 
cytometry analysis. The percentage of cells show activated FAK under basal conditions in 
FLT3WT (i), FLT3ITD vehicle treated cells (ii), and FLT3ITD treated with Y-11 (iii). n=2.
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Fig.2. Inhibition of FAK suppresses the constitutive growth of oncogenic FLT3 and KIT bearing 
cells
(A) BaF3 or (B) 32D cells expressing FLT3WT or FLT3ITD were cultured for 48 hours in 
the presence or absence of F-14 or Y-11 in replicates of four and subjected to a thymidine 
incorporation assay. (C) BaF3 cells co-expressing FRNK and either FLT3ITD or FLT3WT 
were subjected to thymidine incorporation assay as in (A) & (B). (D) WT or FAK−/− BM 
cells expressing FLT3ITD or FLT3WT were subjected to proliferation assay in the absence 
of growth factors as described in (A) & (B). (E) MV4-11 cells expressing endogenous levels 
of FLT3ITD or (F) HL60 cells harboring FLT3WT were subjected to thymidine 
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incorporation assay in presence of Y-11. (G) 32D cells expressing KITD814V or WTKIT 
and (H) HMC1.2 human leukemic cells line harboring KIT (D816V + G560V) mutations 
were cultured in the absence or presence of Y-11, and subjected to thymidine incorporation 
assay. Thymidine incorporation is depicted on y-axis as mean ± SD, *p<0.05. NGF/ No GF= 
cells grown in presence of no growth factors/cytokines. Data are representative of at least 3 
independent experiments.
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Fig.3. AC220 resistant FLT3 mutations, primary AML FLT3ITD+ cells or KITD816V+ SM cells 
are sensitive to FAK inhibition
(A) BaF3 cells bearing FLT3ITD or FLT3 receptors with acquired AC220 resistant 
mutations in the kinase domain (D835Y, F691L and D835V) were subjected to proliferation 
assay as described in Fig 2, *p<0.05. (B) Primary AML patient cells positive for FLT3ITD 
mutation (AML#1-4) or (C) primary KITD816V(+) or KITD816V(-) SM cells were treated 
with indicated concentrations of F-14 or Y-11. After 48 hours proliferation assay was 
performed. Bars denote mean ± SD, *p<0.05.
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Fig.4. Rac1 is a downstream effector of FAK in FLT3ITD bearing oncogenic pathway
(A) BaF3 (lane 1) or 32D (lane 2) cells expressing the FLT3WT receptor or FLT3ITD both 
alone or in combination with FRNK were starved and subjected to a Rac activation assay. 
These cells were either vehicle treated alone (upper panel [CT]) or with F-14 (lower panel) 
(n=2). (B) MV4-11 cells expressing endogenous FLT3ITD, and (C) AML patient FLT3ITD
+ cells were subjected to Rac activation assay as described in (A). (D) FLT3ITD bearing 
BM cells in the setting of FAK deficiency were subjected to Rac activation assay as in (A) 
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(n=2). (E) 32D FLT3ITD cells expressing shRNA's targeting FAK (lane 2, 3) and control 
shRNA (lane 1) were subjected to Rac1 activation assay as described in (A).
Chatterjee et al. Page 25
Cell Rep. Author manuscript; available in PMC 2015 March 31.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig.5. FAK regulates the translocation of active Stat5 and Rac1 to the nucleus in FLT3ITD and 
KITD816V expressing cells
(A) 32D cells expressing FLT3ITD or FLT3WT were serum starved and subjected to 
fractionation assays, and nuclear and cytosolic fractions analyzed for levels of active Stat5 
(pY694), total Stat5 and Rac1, and (B) 32D cells expressing FLT3ITD were subjected to 
fractionation assays after treatment with DMSO control, F-14, FLT3 ligand (FL) or with 
F-14 followed by FL (n=3). (C) HMC1.2 cells bearing KITD816V+G560V mutations, (D) 
MV4-11 and HL60 cells derived from leukemia patients harboring endogenous FLT3ITD 
and FLT3WT mutations were subjected to fractionation assay in presence of F-14 or Y-11 
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as in (A). Fractionation assays were performed in BM cells harvested from primary 
transplanted mice cohorts transplanted with KITD814V in a wild type FAK (FAK+/+) or 
FAK deficient (FAK−/−) background (n=2) (E). Fractionation assay from BM cells 
harvested from F-14 or DMSO (vehicle) treated primary transplant mice cohorts (F). The 
level of Stat5 phosphorylation/expression and Rac1 expression in the nuclear and cytosolic 
fractions is indicated. Expression of GAPDH was used as an indicator of cytosolic marker 
and loading control. ‘MK’ denotes lane with protein ladder. qRT-PCR analysis of relative 
mRNA expression levels of Stat5 responsive genes c-Myc (G) and BclXL (H) in FLT3ITD 
cells treated with F-14 or vehicle (DMSO) (n=2), *p<0.05.
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Fig.6. Downstream of FAK, Tiam1 regulates the activation of Rac1 and subsequent translocation 
of active Stat5 to the nuclear compartment to develop leukemia in mice
(A) Nuclear fractions from F-14 treated FLT3ITD and FLT3WT bearing cells were 
subjected to Rac1 immunoprecipitation assay to assess the level of Rac1 binding to active 
Stat5. Level of active Stat5 (pY694), total Stat5 and Rac1 were analyzed. (B) Active Rac1 
fractions from WT and FAK−/− deficient BM cells expressing FLT3ITD was determined, 
along with levels of active and total Stat5. Total Rac1 levels are shown in the lowermost 
panel (n=2). (C) Fractionation assay was performed using WT and Rac1−/− BM cells 
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expressing FLT3ITD or FLT3WT receptors. Nuclear and cytosolic fractions were analyzed 
as described above. GAPDH was used as a loading control and cytosolic marker (n=3). 
‘MK’ denotes lane with protein ladder. (D) 32D FLT3ITD and FLT3WT cells were treated 
with or without F-14 and subjected to Tiam1 activation assay (n=2). (E) 32D FLT3ITD and 
FLT3WT cells were subjected to Tiam1 IP n presence or absence of F-14. Samples were 
analyzed for amount of Rac1 binding Tiam1 (IP:Tiam1 panels). Lower two panels (Lysate 
(input)) depict the total protein levels of Rac1 and Tiam1 (n=2). (F) 32D cells co-expressing 
FLT3ITD and Tiam1 shRNA or scrambled shRNA were subjected to cellular fractionation 
assay and nuclear and cytosolic fractions were analyzed for the levels of active Stat5 
(pY694), total Stat5 and Rac1, and nuclear marker/loading control PARP-1. (G) 32D cells 
co-expressing FLT3ITD and Tiam1 shRNA's (lanes 2-4) or scrambled shRNA (lane 1) were 
subjected to active Rac1 pull-down assay. The amount of active and total Rac1 are shown in 
the upper and lower panels, respectively. (H) Kaplan-Meier survival curve of mice 
transplanted with 32D cells co-expressing FLT3ITD and Tiam1 shRNA (n=5) or scrambled 
shRNA (n=5), (*p<0.01).
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Fig.7. In vivo inhibition of FAK delays the development of MPN in mice transplanted with 
FLT3ITD and KITD814V bearing cells
(A) C3H/HeJ mice were transplanted with 32D cells bearing FLT3ITD, and treated with 20 
mg/kg body weight F-14 for 28 days. Kaplan-Meier survival analysis of vehicle (n=14) vs. 
F-14 (n=15) treated mice showed significant increase in overall survival (*p<0.02), and 
significant reduction of spleen size and weight (B,C) in F-14 treated mice as compared to 
vehicle (DMSO) control treated mice. (D) BoyJ mice were irradiated and transplanted with 
5-FU treated BM cells expressing KITD814V. Mice were randomly divided into 2 groups 
and treated with vehicle (DMSO) (n=7) or F-14 (n=7) for 3 weeks post-transplantation. 
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Peripheral blood from mice was analyzed at intervals of 2, 4 and 6 weeks (D). After 6 weeks 
mice were harvested to determine spleen size (E) and weight (F). (G) 5-FU treated BM cells 
from WTFAK or FAK−/− mice expressing KITD814V were transplanted into lethally 
irradiated C57BL/6 mice. Kaplan-Meier survival analysis of FAK+/+ KITD814V (n=9) vs. 
FAK−/− KITD814V (n=9) mice, spleen size (H) and weight (I) is shown (*p<0.002). (J) 
Secondary transplants were performed using BM from FAK+/+KITD814V and FAK−/
−KITD814V primary recipients. Kaplan-Meier survival analysis of FAK+/+ KITD814V 
(n=5) vs. FAK−/− KITD814V (n=5) is shown (*p<0.003), and spleen size (K) and weight 
(L) (*p<0.05).
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Fig.8. In vivo inhibition of PAK1 delays the onset of MPN in mice transplanted with FLT3ITD 
bearing cells and inhibits the growth of leukemic patient cells
(A) 32D cells expressing FLT3ITD or FLT3WT were starved of serum and treated with the 
PAK inhibitor IPA-3 (lanes 3,7) alone, with FLT3 ligand (FL) (lanes 2,6), or with IPA-3 
followed by FL (lanes 4,8) as indicated, and subjected to cellular fractionation assay. 
Nuclear and cytosolic fractions were quantitated and equal lysates were loaded on a gel and 
probed with the indicated antibodies. Arrows indicate the activation/expression of the 
labeled molecules in nuclear as well as in cytosolic fractions of FLT3ITD and FLT3WT 
bearing cells. Expression of PARP-1 was used as an indicator of nuclear loading (n=2). (B) 
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32D FLT3ITD and FLT3WT were serum starved and treated with the PAK inhibitor 
PF-3758309 (PF) and analyzed as described in (A). qRT-PCR analysis of relative mRNA 
expression levels of Stat5 responsive genes BclXL (C) and c-Myc (D) in FLT3ITD cells 
treated with PAK inhibitor PF-3758309 (n=2), *p<0.05. Fractionation assays were 
performed in BM cells (E) and splenocytes (F). Mice cohorts transplanted with KITD814V 
in a WT PAK1 (PAK1+/+KIT814V) or PAK1 deficient (PAK1−/−KITD814V) cells (n=2). 
The level of phospho-Stat5, total Stat5 and Rac1 in the nuclear and cytosolic fractions is 
indicated. Expression of GAPDH was used as an indicator of cytosolic marker and loading 
control. ‘MK’ denotes lane with protein ladder. (G) Primary transplant were carried out 
using 5-FU treated BM cells from WTPAK1 or PAK1−/− mice transduced with KITD814V 
or KITWT, and transplanted into lethally irradiated C57BL/6 mice. Four groups of mice 
were used: WTPAK1 KITD814V (n=8), WTPAK1 KITWT (n=5), PAK1−/− KITD814V 
(n=8), and PAK1−/− KITDWT (n=5). Kaplan-Meier survival analysis of PAK1+/+ 
KITD814V vs PAK1−/− KITD814V, WTPAK1 KITWT, PAK1−/−KITWT mice showed 
significant overall survival (*p<0.0003, Hom-Sidak Method), and significant reduction of 
spleen size (H). (I) Secondary transplants were performed using BM cells from PAK1+/
+KITD814V and PAK1−/−KITD814V mice and transplanted into irradiated C57BL/6 mice. 
Kaplan-Meier survival analysis of PAK1+/+ KITD814V (n=5) vs PAK1−/− KITD814V 
(n=5) mice showed significant overall survival (*p<0.001), and significant reduction of 
spleen size (J).
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